Prostate Cancer Research

For enrollment information involving the following trials, please contact a member of our research support staff.


EDRN Upgrading Study


Health Literacy


Validation of FACBC as an Early Indicator of Sub-Clinical Metastatic Disease Among High-Risk Prostate Cancer Patients With Presumed Localized Disease

Inclusion Criteria:

  • High-risk or very-high risk prostate cancer eligible for standard of care surgery

  • At least clinical T3a disease, and/or Gleason >8, and/or PSA>20, as per clinical assessment and routine guidelines

  • Undergone standard of care conventional imaging (CT and/or MR; bone scan and/or NaF PET)

Exclusion Criteria:

  • Definitive findings of systemic metastasis on conventional imaging

Principal Investigator: Mehrdad Alemozaffar, MD

Co-Investigators & Collaborators: David Schuster, MD (Department of Radiology); John Pattaras, MD; Christopher Filson, MD; Kenneth Ogan, MD; Aaron Lay, MD

EDRN Upgrading Study

Biomarkers and Clinical Parameters Associated with Gleason Score Upgrading

Inclusion Criteria:

  • Biopsy-proven Gleason 3+3=6 prostate cancer diagnosed within the past two years

  • Patient scheduled for radical prostatectomy

Exclusion Criteria:

  • Gleason score greater than 3+3=6 on any prior prostate biopsy

  • Any treatment other than radical prostatectomy planned for prostate cancer

  • Prior treatment of the prostate with androgen deprivation, radiation, or other cytotoxic chemotherapy

Principal Investigator: Martin Sanda, MD

Co-Investigator & Collaborator: John Pattaras, MD


Canary Prostate Active Surveillance Study Protocol

Inclusion Criteria:

  • Histologically confirmed adenocarcinoma of the prostate

  • Clinically localized prostate cancer: T1-2; NX or N0, MX or M0

  • No previous treatment for prostate cancer (including hormonal therapy, radiation therapy, surgery, or chemotherapy)

  • Prostate biopsy requirements: (A) If diagnosis within one year of baseline visit, participants must have at least one biopsy within at least 10 cores; (B) If diagnosis more than one year prior to baseline visit, participants must have a minimum of two biopsies, one of which must be within two years prior to baseline visit.

Exclusion Criteria:

  • Unwillingness or inability to undergo serial prostate biopsy

  • History of other malignancies, except: Adequately treated non-melanoma skin cancer or adequately treated superficial bladder cancer (Ta) or other solid tumors curatively treated with no evidence of disease for > five years.

Principal Investigator: Christopher Filson, MD

Co-Investigators & Collaborators: Martin Sanda, MD; John Pattaras, MD

Health Literacy

Improving Health Literacy in African-American Prostate Cancer Patients

Inclusion Criteria:

  • Patients who have undergone pathology review of their prostate biopsy with AJCC clinical stage T1-T2 prostate cancer by physical exam

Exclusion Criteria:

  • Unable to undergo the informed consent process and the study interview in English per the judgment of the primary urologist

  • History of head injury or dementia or history of cognitive impairment

Grady/Emory Principal Investigator: Viraj Master, MD, PhD

Co-Investigators & Collaborators: Mehrdad Alemozaffar, MDKenneth Ogan, MD, Martin Sanda, MD

Atlanta VA Medical Center Principal Investigator: Christopher Filson, MD

««return to top